Loading clinical trials...
Loading clinical trials...
An Open-label, Multi-center Study to Evaluate Sustained Virologic Response With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Genotype 1 Chronic Hepatitis C Virus Infected Patients With Past PI Failure
Conditions
Interventions
12 weeks without Ribavirin
12 weeks with Ribavirin
+1 more
Start Date
January 1, 2016
Primary Completion Date
January 1, 2018
Completion Date
January 1, 2019
Last Updated
January 5, 2016
NCT06953479
NCT03135886
NCT05968573
NCT05042544
NCT05870969
NCT05361603
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions